Conventional therapy with chlorambucil versus fludarabine, used alone or in a novel combination with cyclophosphamide: a randomised controlled trial

Institute of Cancer Research (UK)0 个研究点目标入组 750 人开始时间: 2001年7月1日最近更新: 2018年11月12日

适应症

试验速览

2007 results of assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia in http://www.ncbi.nlm.nih.gov/pubmed/17658394 2. 2008 results on the prognostic significance of a positive direct antiglobulin test in chronic lymphocytic leukemia in http://www.ncbi.nlm.nih.gov/pubmed/18055869 3. 2008 results on the scan of nonsynonymous SNPs in CLL4 trial patients for the identification of genetic variants influencing prognosis in http://www.ncbi.nlm.nih.gov/pubmed/18006695 4. 2008 results on baseline health-related quality of life in http://www.ncbi.nlm.nih.gov/pubmed/19016733 5. 2010 results of identification of prognostic makers in http://www.ncbi.nlm.nih.gov/pubmed/20511662 6. 2010 results of relative importance of prognostic makers in http://www.ncbi.nlm.nih.gov/pubmed/20511662

•1. Patients are diagnosed with B-cell chronic lymphocytic leukaemia
•2. They have not previously been treated
•3. They have been diagnosed by a persistent lymphocytosis and bone marrow infiltration of at least 40% and require treatment
•4. They are classified as having stage A progressive, stage B or stage C disease using the International Binet Staging System
•5. They have given informed consent

•1. Patients with other life-threatening diseases
•2. Patients unable or unwilling to give informed consent
•3. Renal failure (creatinine clearance less than 30 ml/min)
•4. Hepatic enzymes and bilirubin greater than twice the upper limit of normal, unless due to CLL
•5. Pregnant women or women at risk of pregnancy
•6. Patients who for other reasons are not expected to complete the study
•7. Patients with a diagnosis other than CLL after central review of markers and morphology

发起方

Institute of Cancer Research (UK)